News
2hon MSN
Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
'We are in a good spot': Gilead's new chief medical officer is committed to pipeline diversification
Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...
Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...
AI may provide an answer to the question of whether drugs initially developed and prescribed for non-neurodegenerative physical conditions can be used to treat individuals with Parkinson’s disease.
TORL BioTherapeutics LLC (TORL), a clinical-stage biotechnology company discovering and developing new antibody-based immunotherapies to improve and extend the lives of patients with cancer worldwide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback